Accelerating the future of oligonucleotide therapies
Strike Precision Therapeutics (SPTx) has developed an integrated capability to unlock the potential of oligonucleotide therapeutics. We are a specialist contract R&D organisation that can help de-risk the preclinical development of your ASO and siRNA oligonucleotide therapies.
We work with pharma, biotech, techbio and SMEs as well as academic medical centres, research foundations and charities to design, develop and translate oligonucleotide therapies from concept to clinical lead.
What we do
Design
- Define oligonucleotide modality & design strategy
- Optimised design platform for efficacy, off-target and toxicology prediction
- Cross-species homology prediction
- Reduced oligo library complexity
Modification & Conjugation
- Chemical modification to improve stability and uptake, reduce toxicity and immune response
- Conjugation to improve tissue and cell specific delivery
Lead Generation & Optimisation
- On-target efficacy screening
- Dose response – lead identification
- Intracellular localisation
- Cellular toxicity
- Immune activation
in vitro Testing
- Functional analysis: protein rescue & protein knockdown
- Antibody identification and assay optimisation
- iPSC generation
- Functional / biomarker assays in patient-derived cell lines and multicellular organoids
in vivo Testing
- In vivo tolerability
- Biodistribution
- Tissue histopathology
- Clinical biochemistry
- On-target PD / PK assays
Mouse Models of Disease
- Development of humanised mouse models
- Access to mouse models of human genetic diseases
- Comprehensive mouse phenotyping capabilities